Allan Reine

CIK: 0001714023

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (12.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRME

Prime Medicine, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

PRME
Prime Medicine, Inc.
Feb 26, 2026
Award(A)
Stock Option (right to buy)
Direct
1.3M shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
850K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
850K shares-
PRME
Prime Medicine, Inc.
May 21, 2025
Purchase(P)
Direct
125K shares at avg. $1.18$147K
PRME
Prime Medicine, Inc.
May 19, 2025
Award(A)
Stock Option (right to buy)
Direct
2M shares-
PRME
Prime Medicine, Inc.
May 8, 2025
Award(A)
Stock Option (right to buy)
Direct
75K shares-
PRME
Prime Medicine, Inc.
Feb 27, 2025
Award(A)
Stock Option (right to buy)
Direct
275K shares-
PRME
Prime Medicine, Inc.
Dec 5, 2024
Award(A)
Stock Option (right to buy)
Direct
75K shares-

		Type	Shares	Price		Ownership
Feb 26, 2026	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	1,300,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	850,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	850,000	-	-	Direct
May 21, 2025	PRME Prime Medicine, Inc.	Purchase(P)	125,000	$1.18	$147,150	Direct
May 19, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	2,000,000	-	-	Direct
May 8, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	75,000	-	-	Direct
Feb 27, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	275,000	-	-	Direct
Dec 5, 2024	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	75,000	-	-	Direct

1-8 of 8 transactions

About Reine Allan

Reine Allan (SEC CIK 0001714023) files insider reports with the SEC as Chief Executive Officer of Prime Medicine, Inc. (PRME).

Signal8 holds 7 ownership filings by Reine Allan, all Form 4s, filed between Dec 9, 2024 and Feb 27, 2026. Those filings report 8 transactions, from Dec 5, 2024 to Feb 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Reine Allan's filings is in CAMBRIDGE, MA.

Recent filings by Reine Allan

Feb 26, 2026: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
May 21, 2025: Open-market purchase of PRME shares (Form 4, code P).
May 19, 2025: Grant or award of PRME derivative securities (Form 4, code A).

Other insiders filing for Prime Medicine, Inc. (PRME)

Schenkein David P, Director
Marrazzo Jeffrey D, Director
NELSEN ROBERT, Director
Kelly Michael Aaron, Director
Foster-Cheek Kaye I, Director
Chung Wendy, Director

How to read Form 4 transaction codes